Nektar Therapeutics (NKTR) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $66.84 --0%
Revenue Growth %: -11.4%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.53, $0.14 better than the analyst estimate of $0.39. Revenue for the quarter came in at $132.9 million versus the consensus estimate of $123.2 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
- B.Riley on Nayax (NYAX): 'Sell-Off Overshoots the Story'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
